Bioventrix Revivent-TC™ Technology to be Featured during Symposium at the Prestigious German Cardiac Society

SAN RAMON, Calif., April 3,2015BioVentrix, a pioneer of technologies and products for less invasive treatment of heart failure (HF), today announced its participation at the German Cardiac Society (GCS) in Mannheim, Germany April 8-11, 2015 to showcase the Company’s novel procedure known as Less Invasive Ventricular Enhancement™ (LIVE™). The Revivent-TC™ Ventricular Enhancement System reshapes the left ventricle (LV) by using a less invasive hybrid transcatheter approach to treat ischemic heart failure patients following a myocardial infarction. 

The Company is sponsoring a symposium to present the TransCatheter approach to reshaping and restoring the LV.  The focus of the session is to discuss the impact that the LIVE™ procedure has on left ventricular remodeling and the type of patients that can benefit from TransCatheter ventricular enhancement.   

Prof. Karl-Heinz Kuck, Asklepios Klinik St. Georg (Hamburg, Germany) and Prof. Hüseyin Ince, Vivantes Berlin Krankenhaus im Friedrichshain (Berlin, Germany) will be co-chairing the session on April 8, 2015, 17:30-19:00 in Saal 13 room titled Less Invasive Ventricular Enhancement (LIVE): A New Hybrid Therapy for LV Volume Reduction and Reshaping in Ischemic Heart Failure Patients with the following distinguished panel:

  • Prof. Helge Möllmann, Kerckhoff-Klinik (Bad Nauheim, Germany): “The Less Invasive Ventricular Enhancement Procedure: Which Patients are Indicated and How to Perform it?”
  • Prof. Horst Sievert, CardioVascular Center (Frankfurt, Germany): “Overall Clinical Results to Date with the Transcatheter Ventricular Enhancement System.”
  • Prof. Petr Neuzil, Na Homolce Hospital (Prague, Czech Republic): “Initial Single Center Experience with the Transcatheter Ventricular Enhancement System.”
  • Prof. Stefan Anker, University Medical Center Göttingen (Göttingen, Germany): “What is the impact of the Transcatheter Ventricular Enhancement System on ischemic mitral regurgitation?”



“This symposium is a great opportunity to share with our colleagues in Germany about a new therapy option to treat patients suffering from ischemic cardiomyopathy following acute myocardial infarction,” said Prof. Neuzil, the most experienced user of the Revivent technology.  “Left ventricular volume reduction and reshaping is proving to be an effective procedure that strongly impacts Quality of Life when the heart is significantly enlarged due to scarring” continued Prof. Neuzil.

“By offering a closed-chest, hybrid TransCatheter approach, the Revivent-TC system can be accessible to a much broader HF population, those who cannot withstand an invasive surgical procedure” added Prof. Anker, panel representative.  “The symposium covers important information that doctors need to hear about the Revivent-TC system and how LV remodeling has clinically impacted the quality of life of patients who have received this treatment.  This procedure may offer another valuable treatment option in the HF care continuum for physicians to consider,” said Prof. Anker.

Additionally, Dr. Andreas Krüger, Na Homolce Hospital (Prague, Czech Republic) will be presenting an abstract scheduled on April 9, 2015, 16:00-17:30 in Hall 15 room titled Early Clinical Results of Hybrid Transcatheter LV Volume Reduction and Reshaping Procedure for Ischemic Cardiomyopathy vs. Surgical Approach that focuses on comparing the Revivent-TC systems early clinical results to its surgical predecessor, Revivent™ Myocardial Anchoring System.

About the Revivent System and the LIVE Procedure

Placement of the Revivent System via the LIVE procedure obviates the need for more invasive surgery. Instead, small titanium anchors are placed along the outer surface of the heart and along one of the interior walls via a catheter-based approach. The anchors are then pulled toward one another, effectively excluding the scarred and non-functioning heart wall. The efficiency of the remaining heart muscle is immediately improved, by as much as 30-40 percent, according to data presented at the 2014 EuroPCR annual meeting.

Click here for procedural animation

NOTE: The Revivent-TC Ventricular Enhancement System is currently in clinical trial and is not yet commercially available.

To learn more about the Revivent-TC™ system prior to the GCS meeting, please click here.

# # #


Contact: David Schickling, VP of Sales and Marketing, +1-925-830-1000